AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31164156 — intervention group
Group type: EXPERIMENTAL
Intervention: Last time of abortion 2-3 years
Number of subjects: 429
Study 31164156 — intervention group
Group type: EXPERIMENTAL
Intervention: Last time of abortion above 3 years
Number of subjects: 429
Study 28223265 — intervention group
Group type: EXPERIMENTAL
Intervention: AI platform (AiCure)
Number of subjects: 0
Study 28223265 — intervention group
Group type: COMPARATOR
Intervention: mDOT
Number of subjects: 0
Study 25561337 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole 200 mg on day 1 and then 50 mg once daily (arm A)
Number of subjects: 160
Study 25561337 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole 400 mg on day 1 and then 400 mg once-weekly (arm B)
Number of subjects: 160
Study 25561337 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole 400 mg on day 1 and then 100 mg once daily (arm C)
Number of subjects: 160
Study 25561337 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 200 mg on day 1 and then 100 mg once daily (arm D)
Number of subjects: 160
Study 23324133 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of medical care
Number of subjects: 120
Study 23324133 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent medical and chiropractic care
Number of subjects: 120
Study 23324133 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative medical and chiropractic care
Number of subjects: 120
Study 23324133 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 21876476 — intervention group
Group type: EXPERIMENTAL
Intervention: cinacalcet (30 mg daily)
Number of subjects: 10
Study 21876476 — intervention group
Group type: COMPARATOR
Intervention: Control phase without cinacalcet
Number of subjects: 10
Study 19706990 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW 0.8 mg
Number of subjects: 30
Study 19706990 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW 2.0 mg
Number of subjects: 30
Study 19706990 — intervention group
Group type: COMPARATOR
Intervention: Placebo QW
Number of subjects: 30
Study 17885315 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation program starting within the second week after operation
Number of subjects: 300
Study 17885315 — intervention group
Group type: COMPARATOR
Intervention: Late rehabilitation program starting within the fourth week after operation
Number of subjects: 300
Study 17885315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and late rehabilitation programs
Number of subjects: 300
Study 15587227 — intervention group
Group type: COMPARATOR
Intervention: Selective Reminding Test (Buschke 12‐word, six‐trial)
Number of subjects: 75
Study 15587227 — intervention group
Group type: COMPARATOR
Intervention: Performance on alternate forms of the Selective Reminding Test
Number of subjects: 75
Study 15587227 — intervention group
Group type: COMPARATOR
Intervention: Mean education, intelligence quotient, and Wide Range Achievement Test‐3 Reading scores
Number of subjects: 75
Study 11522174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation education and palatal obturation (C1)
Number of subjects: 8
Study 11522174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation education and palatal obturation (C2)
Number of subjects: 8
Study 11522174 — intervention group
Group type: COMPARATOR
Intervention: Haberman bottle feeding (B1)
Number of subjects: 8
Study 11522174 — intervention group
Group type: COMPARATOR
Intervention: Haberman bottle feeding (B2)
Number of subjects: 8
Study 11522174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation education and palatal obturation
Number of subjects: 8
Study 9756250 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g hydrolyzed guar fiber
Number of subjects: 25
Study 9756250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7923804 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon (Alfaferone: Alfa-Wassermann Bologna, Italy) 3 x 10(6) IU by i.m. injection every other day for four weeks (total of 12 injections)
Number of subjects: 42
Study 7923804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3288812 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with postoperative radiation (n = 24)
Number of subjects: 51
Study 3288812 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (n = 27)
Number of subjects: 51
Study 31557450 — intervention group
Group type: EXPERIMENTAL
Intervention: DXM+ (Dexmedetomidine infusion at 4 μg/kg/hr)
Number of subjects: 12
Study 31557450 — intervention group
Group type: COMPARATOR
Intervention: DXM- (Control sedation with midazolam, fentanyl, and propofol)
Number of subjects: 12
Study 31557450 — intervention group
Group type: EXPERIMENTAL
Intervention: DXM+
Number of subjects: 12
Study 31264017 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning with convolutional neural networks (CNN) using midsagittal T1-weighted MRI
Number of subjects: 419
Study 28800383 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2793660 (12 mg once daily for 21 days)
Number of subjects: 10
Study 28800383 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2793660 (single escalating doses from 0.5 to 20 mg)
Number of subjects: 10
Study 28800383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 25747157 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture with a penetrating needle
Number of subjects: 67
Study 25747157 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture with a non-penetrating needle
Number of subjects: 67
Study 23364629 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paricalcitol treatment at doses of 1 mcg/day
Number of subjects: 26
Study 23364629 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ampoule calcifediol/wk (0.266 mg/wk=16 000U) orally
Number of subjects: 26
Study 21636158 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate counting sliding scale (CSc)
Number of subjects: 64
Study 21636158 — intervention group
Group type: COMPARATOR
Intervention: Standard sliding scale (Sc)
Number of subjects: 64
Study 19490137 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: verbal instructions and a self-educational manual on oral hygiene without illustrations
Number of subjects: 53
Study 19490137 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: oral hygiene guidance with verbal instructions and a self-teaching manual
Number of subjects: 53
Study 19490137 — intervention group
Group type: COMPARATOR
Intervention: Control Group I: continued personal oral hygiene routine
Number of subjects: 53
Study 19490137 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 53
Study 17046166 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral micronized progesterone
Number of subjects: 52
Study 15301325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose management protocol (continuous intravenous insulin if glucose >200 mg/dL, target glucose <140 mg/dL)
Number of subjects: 1600
Study 15301325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose management protocol
Number of subjects: 1600
Study 11706484 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Relearning Programme (MRP)
Number of subjects: 61
Study 11706484 — intervention group
Group type: COMPARATOR
Intervention: Bobath method
Number of subjects: 61
Study 11706484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MRP and Bobath)
Number of subjects: 61
Study 9152646 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T < 0.06 (n = 154)
Number of subjects: 963
Study 9152646 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T 0.06-0.2 (n = 175)
Number of subjects: 963
Study 9152646 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T >= 0.2 (n = 437)
Number of subjects: 963
Study 9152646 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk exercise test response (n = 361)
Number of subjects: 963
Study 9152646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate risk exercise test response (n = 325)
Number of subjects: 963
Study 9152646 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk exercise test response (n = 80)
Number of subjects: 963
Study 9152646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of troponin T and exercise test response (Low risk n = 84)
Number of subjects: 963
Study 9152646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of troponin T and exercise test response (Intermediate risk n = 406)
Number of subjects: 963
Study 9152646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of troponin T and exercise test response (High risk n = 276)
Number of subjects: 963
Study 9152646 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T < 0.06 in patients unable to perform exercise test (n = 197)
Number of subjects: 963
Study 9152646 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T 0.06-0.2 in patients unable to perform exercise test (n = 197)
Number of subjects: 963
Study 9152646 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T >= 0.2 in patients unable to perform exercise test (n = 197)
Number of subjects: 963
Study 8490912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg plus clindamycin 600 mg every 8 hours
Number of subjects: 83
Study 8490912 — intervention group
Group type: COMPARATOR
Intervention: IV aztreonam 2 g plus clindamycin 600 mg every 8 hours
Number of subjects: 83
Study 8490912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral regimen
Number of subjects: 83
Study 8490912 — intervention group
Group type: COMPARATOR
Intervention: IV regimen
Number of subjects: 83
Study 3124734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g intravenously every 12 hours
Number of subjects: 28
Study 31542816 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible reamers
Number of subjects: 50
Study 31542816 — intervention group
Group type: COMPARATOR
Intervention: Rigid reamers
Number of subjects: 50
Study 29611275 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapy (ADT)
Number of subjects: 597
Study 27316224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sodium citrate solution
Number of subjects: 57
Study 27316224 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride solution (placebo control)
Number of subjects: 57
Study 25195371 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Qianlongtong Capsule (6 capsules once, tid for 7 days)
Number of subjects: 15
Study 25195371 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose Qianlongtong Capsule (3 capsules once, tid for 7 days)
Number of subjects: 15
Study 25195371 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Qianlongtong Capsule (1.5 capsules once, tid for 7 days)
Number of subjects: 15
Study 25195371 — intervention group
Group type: COMPARATOR
Intervention: Blank control group (no QLT)
Number of subjects: 15
Study 22422075 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year mortality predictive index
Number of subjects: 7373
Study 22422075 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year mortality predictive index
Number of subjects: 7373
Study 22422075 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-year mortality predictive index
Number of subjects: 7373
Study 20872114 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine
Number of subjects: 0
Study 20872114 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 0
Study 18592210 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheotomy (ET) within 4 days
Number of subjects: 123
Study 18592210 — intervention group
Group type: COMPARATOR
Intervention: Prolonged intubation (PI)
Number of subjects: 123
Study 18592210 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheotomy (ET)
Number of subjects: 123
Study 15801915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg continuous treatment (once daily)
Number of subjects: 176
Study 15801915 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg on-demand treatment
Number of subjects: 176
Study 15801915 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 176
Study 15801915 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment
Number of subjects: 176
Study 15801915 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality of life score
Number of subjects: 176
Study 12451189 — intervention group
Group type: COMPARATOR
Intervention: IFNbeta‐1a 30 micro g IM once weekly
Number of subjects: 802
Study 12451189 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 60 micro g IM once weekly
Number of subjects: 802
Study 12451189 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measure at month 36
Number of subjects: 802
Study 11019837 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim-mobilized PBSCT
Number of subjects: 39
Study 11019837 — intervention group
Group type: COMPARATOR
Intervention: BMT
Number of subjects: 39
Study 11019837 — intervention group
Group type: EXPERIMENTAL
Intervention: <2 x 10(6) CD34+ cells/kg
Number of subjects: 39
Study 11019837 — intervention group
Group type: COMPARATOR
Intervention: >=2 x 10(6) CD34+ cells/kg
Number of subjects: 39
Study 11019837 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ cell dose >=2 x 10(6)/kg
Number of subjects: 39
Study 9260226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulfate (FS) solution for 15 sec, rinsed, and covered by zinc oxide‐eugenol paste (ZOE)
Number of subjects: 72
Study 9260226 — intervention group
Group type: COMPARATOR
Intervention: Dilute formocresol (DFC) with a cotton pellet moistened with 20% for 5 min, removed, and pulp stumps covered by ZOE paste
Number of subjects: 72
Study 1441366 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 50
Study 1441366 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymalin (immunomodulators)
Number of subjects: 50
Study 3549399 — intervention group
Group type: EXPERIMENTAL
Intervention: New trivalent vaccine produced exclusively on human tissue
Number of subjects: 120
Study 3549399 — intervention group
Group type: COMPARATOR
Intervention: Commercially available M-M-R-II vaccine produced by MSD
Number of subjects: 120
Study 30502978 — intervention group
Group type: EXPERIMENTAL
Intervention: PCpIOL implantation (Visian ICL/TICL of V4C design)
Number of subjects: 30
Study 30502978 — intervention group
Group type: COMPARATOR
Intervention: SMILE procedure
Number of subjects: 30
Study 30502978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 26820305 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprout homogenates (BSH)
Number of subjects: 29
Study 26820305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alfalfa sprout homogenate, ASH)
Number of subjects: 29
Study 26820305 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza virus (LAIV)
Number of subjects: 29
Study 24281139 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insulin therapy
Number of subjects: 38
Study 24281139 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 38
Study 23051991 — intervention group
Group type: EXPERIMENTAL
Intervention: NA-1 (Tat-NR2B9c) intravenous infusion
Number of subjects: 185
Study 23051991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline control)
Number of subjects: 185
Study 20556417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry
Number of subjects: 9
Study 20556417 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise
Number of subjects: 9
Study 18705272 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg diacerein tablets administered twice daily for 12 weeks
Number of subjects: 7923
Study 15815185 — intervention group
Group type: EXPERIMENTAL
Intervention: COH-BMT
Number of subjects: 92
Study 15815185 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-BMT
Number of subjects: 92
Study 15815185 — intervention group
Group type: COMPARATOR
Intervention: MOS-SF-36
Number of subjects: 92
Study 15815185 — intervention group
Group type: EXPERIMENTAL
Intervention: COH-BMT and FACT-BMT
Number of subjects: 92
Study 14960007 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% mandibular advancement
Number of subjects: 74
Study 14960007 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% mandibular advancement
Number of subjects: 74
Study 10767507 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted vaginal hysterectomy (LAVH)
Number of subjects: 70
Study 10767507 — intervention group
Group type: COMPARATOR
Intervention: Vaginally assisted laparoscopic hysterectomy (VALH)
Number of subjects: 70
Study 8803363 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive intervention
Number of subjects: 54
Study 8803363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 54
Study 8803363 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 54
Study 31791333 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D fortified foods (30 μg vitamin D3/day through fortified yoghurt, cheese, eggs, and crisp-bread)
Number of subjects: 143
Study 31791333 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D fortified foods
Number of subjects: 143
Study 30032193 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 addback during aromatase inhibition
Number of subjects: 74
Study 26163352 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM‐tailored computerized intervention at baseline, 6 months, and 12 months
Number of subjects: 1894
Study 26163352 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM‐tailored computerized intervention
Number of subjects: 1894
Study 25150151 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI after 3 cycles and post-NAC
Number of subjects: 250
Study 25150151 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 250
Study 22216905 — intervention group
Group type: EXPERIMENTAL
Intervention: Online decision aid 'zelftestwijzer'
Number of subjects: 0
Study 22216905 — intervention group
Group type: COMPARATOR
Intervention: Short, non-interactive information on self-testing
Number of subjects: 0
Study 18937229 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node nanometastases
Number of subjects: 0
Study 18937229 — intervention group
Group type: COMPARATOR
Intervention: Literature data set on prostate cancer
Number of subjects: 0
Study 16870959 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant psychotropic medications (82% of patients)
Number of subjects: 1380
Study 16870959 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics
Number of subjects: 1380
Study 16870959 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety or depression
Number of subjects: 1380
Study 16870959 — intervention group
Group type: EXPERIMENTAL
Intervention: Better neurocognitive functioning
Number of subjects: 1380
Study 16870959 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms likely targets of polypharmacy (e.g., depression)
Number of subjects: 1380
Study 12600855 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg Cu/L water
Number of subjects: 1365
Study 12600855 — intervention group
Group type: COMPARATOR
Intervention: <0.01 mg Cu/L water
Number of subjects: 1365
Study 12600855 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intake
Number of subjects: 1365
Study 12600855 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-load variables
Number of subjects: 1365
Study 12600855 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver function tests
Number of subjects: 1365
Study 12600855 — intervention group
Group type: EXPERIMENTAL
Intervention: Superoxide dismutase activity
Number of subjects: 1365
Study 10953652 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable intraoral appliances that advance the mandible during sleep
Number of subjects: 0
Study 10953652 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with continuous positive airway pressure (CPAP)
Number of subjects: 0
Study 9365348 — intervention group
Group type: EXPERIMENTAL
Intervention: Local heat application over the right palm
Number of subjects: 20
Study 9365348 — intervention group
Group type: COMPARATOR
Intervention: Control group (contralateral hand)
Number of subjects: 20
Study 1399664 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 30
Study 1399664 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 30
Study 1399664 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 30
Study 3886068 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mm suction drain left in the gallbladder bed
Number of subjects: 155
Study 3886068 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 155
Study 29667233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd blood stopper (ABS)
Number of subjects: 630
Study 29667233 — intervention group
Group type: COMPARATOR
Intervention: Conventional sterile gauzes (CSG)
Number of subjects: 630
Study 29667233 — intervention group
Group type: COMPARATOR
Intervention: TR Band
Number of subjects: 630
Study 26916657 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (1.5 ml/s)
Number of subjects: 51
Study 26916657 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (2.0 ml/s)
Number of subjects: 51
Study 26916657 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (3.0 ml/s)
Number of subjects: 51
Study 25318111 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration of intravenous (IV) antibiotics (125 hours)
Number of subjects: 142
Study 25318111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound ordered (85%)
Number of subjects: 142
Study 25318111 — intervention group
Group type: EXPERIMENTAL
Intervention: Voiding cystourethrogram (VCUG) ordered (61%)
Number of subjects: 142
Study 25318111 — intervention group
Group type: EXPERIMENTAL
Intervention: Consult requested (54%)
Number of subjects: 142
Study 25318111 — intervention group
Group type: EXPERIMENTAL
Intervention: Wait for VCUG (53 hours)
Number of subjects: 142
Study 25318111 — intervention group
Group type: EXPERIMENTAL
Intervention: Born preterm (13%)
Number of subjects: 142
Study 25318111 — intervention group
Group type: EXPERIMENTAL
Intervention: Known genitourinary disease (17%)
Number of subjects: 142
Study 25318111 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age (4.2 weeks)
Number of subjects: 142